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 The age of hypocrisy has been succeeded by that of indifference, which is worse, 
for indifference corrupts and appeases: it kills the spirit before it kills the body. 
It has been stated before, it bears repeating: the opposite of love is not hate, but 
indifference.  —Elie Wiesel 
 The last ﬁ ve years have witnessed increased efforts by G8 nations and United Nations agencies to improve the health of the world’s 3 billion people living on 
less than US$2 a day. Most of this attention has focused on 
efforts to intensify resources for ﬁ ghting the three most 
devastating diseases: HIV/AIDS, tuberculosis, and malaria. 
Together, these “big three” account for a staggering 5.6 
million deaths and the loss of 166 million disability-adjusted 
life years (DALYs) annually (see annex tables 2 and 3 in 
[1]). Prominent partnerships and initiatives are now devoted 
to the big three (Box 1), and increased global attention to 
these diseases (and to the risks posed by avian inﬂ uenza and 
other emerging viral infections) culminated in the November 
2005  TIME Global Health Summit, branded by Bono as 
the “Woodstock of Global Health” (http:⁄⁄www.time.com/
time/2005/globalhealth). 
 These new initiatives and “Woodstock” Global Health have 
done much to raise funds and elevate public awareness in 
order to launch a serious war on the big three. Conspicuously 
absent from these activities, however, has been commensurate 
advocacy for a group of diseases that exclusively affect the 
poor and the powerless in rural and impoverished urban 
areas of developing countries. An increasing body of evidence 
indicates that this group of “neglected tropical diseases” may 
not only threaten the health of the poor as much as HIV/
AIDS, tuberculosis, or malaria, but even more importantly, 
may have effective treatment and prevention strategies that 
can be delivered for less than US$1 per capita per year. 
Furthermore, new evidence points to substantial geographic 
overlap between the neglected tropical diseases and the big 
three, with emerging data suggesting that control of the 
neglected tropical diseases could actually become a powerful 
tool for combating HIV/AIDS, tuberculosis, and malaria. 
The Neglected Diseases section focuses attention either on a speciﬁ c disease or 
describes a novel strategy for approaching neglected health issues in general.
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 Box 1. Prominent Partnerships and Initiatives 
Devoted to the “Big Three”
 •  The Joint UN Programme on HIV/AIDS (http://www.unaids.
org)
 •  Roll Back Malaria (http://www.rollbackmalaria.org)
 •  Stop Tuberculosis (http://www.stoptb.org)
 •  The Global Fund to Fight AIDS, Tuberculosis, and Malaria 
(So far has attracted US$4.7 billion in ﬁ nancing through 2008 
[http://www.theglobalfund.org]) 
 •  The US Leadership against HIV/AIDS, Tuberculosis, and 
Malaria Act of 2003 (An emergency effort to provide US$15 
billion over ﬁ ve years [http://olpa.od.nih.gov/actions/public/
108session1/pl108-25.asp]), 
 •  The President’s Emergency Plan for AIDS Relief (http://
www.avert.org/pepfar.htm), 
 •  The Bill and Melinda Gates Foundation (http://www.
gatesfoundation.org), supporting the development of new 
technologies for disease control.  
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Therefore, achieving success in the global ﬁ ght against 
HIV/AIDS, tuberculosis, and malaria may well require a 
concurrent attack on the neglected tropical diseases and 
waging a larger battle against a new 21st century “gang of 
four.” 
 Global Burden of the Neglected Tropical Diseases
 The most important neglected tropical diseases include 
three vector-borne protozoan infections—leishmaniasis, 
human African trypanosomiasis, and Chagas disease; three 
bacterial infections—trachoma, leprosy, and Buruli ulcer; 
and seven helminth infections—hookworm, ascariasis, 
trichuriasis, lymphatic ﬁ lariasis, onchocerciasis, guinea worm 
(drancunculiasis), and schistosomiasis [2]. Cysticercosis, 
food-borne trematodiases, and some other parasitic infections 
could also be included in this list [3–5]. The common 
features of the neglected tropical diseases include high 
endemicity in rural and in impoverished urban areas of low-
income countries, and an ability to impair childhood growth, 
intellectual development, and education, as well as worker 
productivity. In this way, the neglected tropical diseases 
are poverty-promoting conditions. Many of the neglected 
tropical diseases are disﬁ guring and stigmatizing—their 
characteristic features are described in the Bible and other 
ancient texts, afﬁ rming that they have affected humans for 
millennia [2]. However, because they affect the poorest of 
the poor, there are few or no commercial markets for drugs 
and vaccines against the neglected tropical diseases, and the 
pharmacopoeia for these diseases has remained essentially 
unchanged since the middle of the 20th century [2]. 
 The burden of disease resulting from the neglected 
tropical diseases is huge. As shown in Table 1, they cause 
approximately 534,000 deaths annually, with ﬁ ve diseases—
schistosomiasis, hookworm, ascariasis, leishmaniasis, and 
human African trypanosomiasis—accounting for more than 
400,000 deaths. Even more signiﬁ cant than the mortality 
burden are the years of life lost that result from premature 
disability. By some estimates, the neglected tropical diseases 
are second only to HIV/AIDS as a cause of disease burden, 
resulting in approximately 57 million DALYs annually [8]. If 
considered together, the neglected tropical diseases would 
represent the fourth most important group of communicable 
diseases worldwide, behind lower respiratory infections, HIV/
AIDS, and diarrheal diseases (Table 2). 
 Epidemiologic Overlap and Comorbidity of the 
Neglected Tropical Diseases, and Opportunities 
for Integrated Control
 The neglected tropical diseases do not occur in isolation. 
In most countries of sub-Saharan Africa, and in many 
other tropical and subtropical countries, at least ﬁ ve to six 
neglected tropical diseases occur in the same region [9]. The 
implication of this geographic overlap is that a considerable 
proportion of the population of sub-Saharan Africa (and 
selected regions of Asia and the Americas) is polyparasitized 
with one or more soil-transmitted helminths (STHs), 
schistosomes, and ﬁ larial worms [10–14], particularly among 
the very poorest populations [15–17]. Each of the three 
major STHs  (Ascaris lumbricoides, Trichuris trichiura, and the 
hookworms,  Necator americanus and  Ancylostoma duodenale) and 
the two schistosomes  (Schistosoma haematobium and  Schistosoma 
mansoni) are highly endemic to sub-Saharan Africa, where 
they adversely affect childhood growth and physical ﬁ tness 
[18–24]. Such polyparasitism has a substantial impact on 
the physical health of Africa’s youth population [25], as 
well as on the impairment of their intellectual and cognitive 
development [26–30]. Polyparasitism also results in anemia 
[31], with hookworms being well-known causes of anemia 
because of intestinal blood loss [32], though  T. trichiura and 
 S. mansoni also cause some degree of intestinal blood loss [33–
35], and  S. haematobium causes anemia through hematuria 
[36]. In addition to host blood loss, the schistosomes also 
probably cause anemia through other mechanisms including 
hypersplenism, red blood cell sequestration, autoimmune 
hemolysis, and chronic inﬂ ammation [36,37]. 
 Documented improvements in childhood growth [18,20], 
physical ﬁ tness [19,21], cognition [26–30], school attendance 
[38], and hemoglobin and serum ferritin concentrations 
[39–41] following deworming, together with a theoretical 
framework of helminth transmission dynamics [42,43], 
provided the basis for a World Health Assembly resolution 
adopted in 2001 urging member states to periodically deworm 
school-age children with a benzimidazole anthelmintic 
(either albendazole or mebendazole) and praziquantel as a 
means for reducing global disease burden (http:⁄⁄www.who.
int/wormcontrol) [44]. Periodic deworming also provides 
the basic strategy of the Schistosomiasis Control Initiative 
(http:⁄⁄www.schisto.org) in Africa [13]. 
 Lymphatic ﬁ lariasis (LF), onchocerciasis, and trachoma 
exhibit considerable geographic overlap with the STHs 
and schistosomiasis [9]. Therefore, the combination of 
ivermectin and albendazole for the elimination of LF in 
Africa and ivermectin for onchocerciasis control—the 
cornerstones of the Global Programme to Eliminate 
Lymphatic Filariasis (http:⁄⁄www.ﬁ lariasis.org) and the 
 Table 1.  Disease Burden of the Neglected Tropical Diseases 
in Deaths and DALYs  
Variable Deaths DALYsa
Schistosomiasis 280,000b  4.5 millionc
Hookworm infection 65,000c 22.1 millionc,d
Ascariasis 60,000c 10.5 millionc,d
Leishmaniasis 51,000e 2.1 millionf
Trypanosomiasis 48,000c 1.5 millionf
Chagas disease 14,000c 0.7 millionf
Trichuriaisis 10,000b 6.4 millionc,d
Leprosy 6,000c  0.2 millionf
Lymphatic ﬁ lariasis  0c 5.8 millionf
Trachoma 0c 2.3 millionf
Onchocerciasis 0c 0.5 millionf
Drancunculiasis ND < 0.1 millionf
Buruli ulcer ND ND
Taeniasis and cysticercosis ND ND
Food-borne trematodiases ND ND
Total 534,000 56.6 million
 aMany of the current DALY estimates for the neglected tropical diseases are probably underestimates 
because they do not fully consider the long-term chronic disabilities [24]. Together, the World Health 
Organization and the Ellison Institute for World Health at Harvard University have embarked on an 
initiative to reassess the disease burden in developing countries, including the DALYs lost from neglected 
tropical diseases. 
 bEstimates for Africa only [125]
 c[6]
 d[126] The schistosomiasis DALY ﬁ gures were also quoted in [126], but were originally cited in [7].
 eAnnex table 2 [1]. Estimates of death from schistosomiasis, hookworm infection, ascariasis, and 
trichuriasis were also provided in this reference but are not quoted here. 
 fAnnex table 3 in [1]. DALY estimates for hookworm disease, ascariasis, trichuriasis, and schistosomiasis are 
also provided in annex table 3 but are not quoted here. 
 ND, not determined
 DOI: 10.1371/journal.pmed.0030102.t001 
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African Programme for Onchocerciasis Control (http:⁄⁄www.
apoc.bf/en), respectively—add considerable beneﬁ ts to the 
treatment of ascariasis and trichuriasis [45]. At the same 
time, combinations of ivermectin and azithromycin prevent 
blindness by reducing the incidence of onchocerciasis 
and trachoma, respectively [46]. Through its impact on 
ectoparasite infections, ivermectin also indirectly helps to 
reduce the frequency and severity of skin infections [45,47]. 
 Based on the substantial morbidity reductions afforded 
by reducing polyparasitism, Molyneux et al. [9] have 
recently put forward a comprehensive pro-poor strategy 
to integrate programs for either the control or the 
elimination of seven neglected tropical diseases—ascariasis, 
trichuriasis, hookworm, lymphatic ﬁ lariasis, onchocerciasis, 
schistosomiasis, and trachoma—using existing drugs. Such 
integration efforts are particularly relevant to sub-Saharan 
Africa because the neglected tropical diseases in this 
region exhibit a high degree of geographic overlap [9]. 
It is proposed that such integrated control or elimination 
could be achieved with four drugs—ivermectin, albendazole, 
azithromycin, and praziquantel—of which three are currently 
donated by Merck and Company, GlaxoSmithKline, and 
Pﬁ zer, respectively, while praziquantel is available at relatively 
low cost [12]. Each of the drugs has overlapping speciﬁ city 
so that multiple neglected pathogens would be concurrently 
targeted. In addition, the four-drug regimen would also 
target ectoparasite infections, such as scabies, pediculosis, 
tungiasis, and cutaneous larva migrans, and their resulting 
secondary bacterial skin infections [45,47], and possibly also 
affect important respiratory bacterial pathogens including 
pneumococcus [9]. It has been estimated that for US$200 
million annually, approximately 500 million Africans 
(US$0.40 per patient) could be treated in a four-drug 
integrated pro-poor package [9,12]. That package could 
reduce tens of millions of DALYs annually and simultaneously 
address seven of the eight Millennium Development Goals 
(MDGs), including those related to poverty reduction, 
educational achievement, and child and maternal health [9]. 
This approach has been recommended by the Commission 
for Africa [48], and a  Lancet editorial has emphasized that 
deworming is a prerequisite for improved health of the 
world’s poorest children and is one of the “quick wins” 
identiﬁ ed in the Millennium Project Report [49,50]. 
 As scaling up integrated control moves forward, a 
number of research and monitoring questions will need 
to be addressed, including issues of compliance [51], 
drug interactions, emerging drug resistance [52], and 
sustainability. Moreover, proof of concept for the feasibility 
of integrated control will require attention to the speciﬁ c 
populations (e.g., children versus adults) at risk for each 
of the neglected tropical diseases, and to the timing for 
administration of each of the four drugs. Equally important 
will be undertaking an economic analysis of the rapid-impact 
package. The studies on the economic rates of return of 
large-scale and successful neglected tropical disease control 
and elimination programs, such as onchocerciasis control in 
West Africa, guinea worm eradication, LF, and schistosomiasis 
control in Egypt and China, and Chagas disease control in 
South America, have shown that these are of the order of 
15%–30% [53]. The World Bank and other agencies have 
recognized these programs as being among the most effective 
development investments in any sector [53], and it is hoped 
that an equal or greater rate of return could be achieved 
with a rapid-impact package targeting multiple neglected 
tropical diseases [9]. In the future, the concept of integration 
could be expanded beyond integrated chemotherapy-based 
morbidity control based largely on community-directed 
treatment to include access to clean water and improved 
sanitation; strengthening of surveillance, evaluation, and 
reporting systems; capacity building, deployment of new 
generation control tools; and education and communication 
strategies to address the root ecological and behavioral causes 
of the neglected tropical diseases (J. Utzinger, personal 
communication) [17,54,55].
 Epidemiologic Overlap of the Neglected Tropical 
Diseases with HIV/AIDS, Tuberculosis, and Malaria
 In many parts of the developing world, but especially in 
sub-Saharan Africa, the geographic overlap between HIV/
AIDS, tuberculosis, and malaria is extensive. Indeed, Africa’s 
catastrophic burden of disease resulting from HIV-associated 
tuberculosis [56] and severe malaria in individuals with 
HIV [57–59] is emerging as one of the ﬁ rst great human 
tragedies of the 21st century. Adding to the complexity 
of Africa’s big three is the geographic and epidemiologic 
overlay of the neglected tropical diseases (S. Brooker, A. C. A. 
Clements, P. J. Hotez, S. I. Hay, A. Tatem, et al., unpublished 
data) [60,61]. It has become increasingly clear that HIV/
AIDS, tuberculosis, and malaria occur predominantly in 
populations who are polyparasitized [11,62,63]. Helminths 
are the most common parasites found in HIV-, tuberculosis-, 
and malaria-infected populations  (S. Brooker, A. C. A. 
Clements, P. J. Hotez, S. I. Hay, A. Tatem, et al., unpublished 
data) [11,62,63], especially the three major STHs [64–66], 
the two major schistosomes [67–69], and the ﬁ lariae [70]. 
Brooker and colleagues have recently demonstrated a close 
geographical overlap in Africa between hookworm and 
malaria (S. Brooker, A. C. A. Clements, P. J. Hotez, S. I. Hay, 
A. Tatem, et al., unpublished data). However, almost all of 
the major neglected tropical diseases have been linked with 
the big three. 
 Comorbidity of the Neglected Tropical Diseases with 
HIV/AIDS, Tuberculosis, and Malaria: Anemia
 We are still in the early stages of appreciating the full extent 
of the comorbidity that occurs when the neglected tropical 
diseases are superimposed on HIV/AIDS, tuberculosis, and 
malaria [71]. Anemia has been revealed as perhaps the most 
important of the leading comorbid conditions. Among the 
neglected tropical diseases, hookworm, schistosomiasis, 
 Table 2.  Comparative Disease Burdens of Communicable 
Diseases Measured in DALYs 
Disease Condition Disease Burden
Lower respiratory infections 91.3 milliona
HIV-AIDS 84.5 milliona
Diarrheal diseases 62 milliona
Neglected tropical diseases 56.6 millionb
Malaria 46.5 milliona
Tuberculosis 34.7 milliona
Measles 21.4 milliona
 aAnnex table 3 in [1]
 bData derived from Table 1 and [8].
 DOI: 10.1371/journal.pmed.0030102.t002 
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kala-azar, and trypanosomiasis are major causes of anemia 
[32,35,72,73], with hookworm accounting for up to 35% 
and 73% of the iron-deﬁ ciency anemia and severe iron-
deﬁ ciency anemia in Africa, respectively [74]. Children 
and pregnant women are particularly susceptible to anemia 
from hookworm and schistosomiasis [35,74,75]. As noted 
already, hookworm causes iron-deﬁ ciency anemia through 
intestinal blood loss, while the mechanisms of anemia from 
the other neglected tropical diseases are more complex. 
Each of the big three also results in anemia, with malaria 
responsible for the greatest burden. Malaria causes anemia 
by several different mechanisms, including increased 
destruction of both parasitized and nonparasitized red blood 
cells and dyserythropoiesis resulting from host production 
of inﬂ ammatory cytokines, especially tumor necrosis factor 
and macrophage migration inhibitory factor [76,77]. The 
pathogenesis of anemia from HIV/AIDS and tuberculosis is 
also complex, most likely resulting from a state of chronic 
inﬂ ammation leading to bone marrow suppression [36]. 
 A major consequence of polyparasitism, therefore, is 
anemia from multiple infectious causes. In the case of 
hookworm and malaria, Brooker et al. (S. Brooker, A. C. A. 
Clements, P. J. Hotez, S. I. Hay, A. Tatem, et al., unpublished 
data) have shown that in Kenya the two types of anemia—
anemia from hookworm and the anemia from malaria—can 
build on each other to produce profound reductions in 
hemoglobin. To make matters worse, many of these same 
African populations experience further reductions in 
hemoglobin because of sickle cell disease and thalassemia, 
as well as nutritional deﬁ cits in iron and folate. Fleming 
[78] put forward the concept of the “agriculture-related 
anemias” to describe this “perfect storm” confronting African 
populations—changes in diet, population growth with limited 
sanitation and with the consequences of endemic STH 
infections, an environment prone to the emergence of vector-
borne disease, and natural selection of variants that offer 
partial protection against malaria—all of which resulted from 
the introduction of agriculture, beginning at the time of the 
Neolithic Revolution. 
 The severe anemia resulting from helminth polyparasitism 
and malaria produces several adverse health consequences 
among three particularly important African subpopulations: 
pregnant women, children, and individuals with HIV. In 
pregnancy, anemia is a leading contributor to maternal 
morbidity and mortality, and is associated with shock, risk 
of cardiac failure, decreased ability to work, and adverse 
perinatal outcomes [79]. In coastal Kenya, malaria was 
identiﬁ ed as the most important cause of anemia in 
primigravidae, whereas hookworm attained increased 
importance among multigravidae [79,80]. Therefore, 
women are put at risk by the major consequences of anemia 
throughout their childbearing years. In young children, 
chronic iron deﬁ ciency and anemia are associated with 
increased child mortality, and impairments in physical 
growth, cognitive and motor development, immune function, 
and school performance [81–84]. Severe anemia is also a 
major contributor to mortality from malaria [85]. Just as 
women are at risk for anemia throughout their childbearing 
years, ﬁ rst from malaria and then from hookworm, so, 
too, are children whose ﬁ rst major experience with severe 
anemia is from malaria during early childhood, followed 
by hookworm and schistosomiasis in middle childhood and 
adolescence. Together, these infectious anemias account for 
an important component of the “silent burden of anemia” in 
African children [86]. Finally, among individuals with HIV, 
anemia has been shown to be an independent risk factor for 
early death, with correction of anemia associated with reversal 
of increased risk [87,88]. 
 Impact of the Neglected Tropical Diseases on Host 
Susceptibility to HIV/AIDS, Tuberculosis, and Malaria
 Coinfection with the neglected tropical diseases also 
adversely affects the natural history and progression of the 
big three. Several studies (recently reviewed in [62]) point 
to the increasing severity of clinical malaria that results 
from helminth coinfection. These studies include those 
from Senegal showing enhanced risk or increased incidence 
of clinical malaria resulting from either STH [64,66] or 
schistosome [68] infections, unpublished studies from 
Malawi showing that women infected with hookworms were 
at 1.8 times higher risk of having malaria than uninfected 
women [89], and studies from Thailand showing increased 
susceptibility to malaria in patients with STH infections 
[90–93]. 
 However, not all studies investigating these relationships 
have identiﬁ ed deleterious interactions between helminths 
and malaria [63,69,94,95]. Indeed, there may be a difference 
between helminthic effects on susceptibility to malaria 
and effects on the pathology induced by malaria infection. 
Druilhe et al. [62] have hypothesized that the STHs and 
schistosomes immunomodulate the host to increase malaria 
susceptibility by shifting their humoral responses from 
malaria-protective, cytophilic humoral antibodies (IgG1 
and IgG3) to nonprotective, noncytophilic subclasses 
(IgG2 , IgG4, and IgM). In addition, Diallo et al. [67] have 
proposed that schistosomes, and possibly other helminths, 
can unbalance the regulation of inﬂ ammatory cytokines in 
childhood malaria. 
 Another body of evidence links helminth coinfections 
with increased susceptibility to HIV/AIDS or worsening 
progression of HIV disease (reviewed in [65]). Borkow 
and Bentwich postulate that chronic helminth infections 
increase the risk of HIV infection through a process of 
chronic immune activation [96], which results in increased 
HIV plasma viral load [97–99]. Among a group of Kenyan 
car washers with high levels of exposure to  S. mansoni 
infection, Secor et al. [100] have shown that patients with 
active schistosomiasis exhibit increased expression of the 
chemokine receptors and HIV-1 co-receptors, CCR5 and 
CXCR4, on peripheral blood CD4 T cells and monocytes. 
Gallagher et al. [101] observed increased risk of mother-to-
child HIV transmission in pregnant women with helminth 
coinfection; increased risk correlated with cord blood 
lymphocyte production of interleukin-5 and interleukin-13 in 
response to helminth antigens. However, studies conducted 
in Uganda failed to identify an association between helminths 
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and AIDS [102,103]. In addition to promoting susceptibility 
to HIV/AIDS, one major neglected tropical disease in Africa, 
namely, visceral leishmaniasis, is an important opportunistic 
infection in individuals who are HIV-immunocompromised 
[72].
 Finally, there is some evidence that helminth infections, 
especially hookworm and schistosomiasis, adversely affect the 
outcome of pulmonary tuberculosis or the progression to 
active tuberculosis [104,105], and reduce the T cell responses 
in individuals receiving Bacillus Calmette–Gurerin (BCG) 
[106–108]. However, the data supporting this concept is still 
far from conclusive.
 Taken together, this evidence indicates that coinfection 
with one or more neglected tropical disease may profoundly 
affect the outcome of one or more of the big three. 
Progression of disease from HIV/AIDS, tuberculosis, 
and malaria results from the comorbidity associated with 
anemia from hookworm, trichuriasis, schistosomiasis, 
trypanosomiasis, and leishmaniasis, and from the possible 
increase in susceptibility and worsening progression of disease 
that occurs with STH, schistosome, and ﬁ larial infections. 
However, the latter concept is still not without controversy 
and requires additional scientiﬁ c investigations. 
 A Comprehensive Pro-Poor Health Policy 
 It is important to determine if there is a rationale for linking 
a pro-poor strategy for integrated neglected tropical disease 
control with ongoing programs that target the big three. 
Recent evidence of the extensive geographic overlap between 
the big three and the neglected tropical diseases, together 
with the deleterious interactions between both groups of 
infections, suggests signiﬁ cant, new opportunities to reduce 
the burden of disease in sub-Saharan Africa and elsewhere 
in the developing world. Success at integrating neglected 
tropical disease control into big three partnership programs 
could dramatically reduce the number of life years lost from 
premature death and disability in Africa [9]. The collateral 
beneﬁ ts from including neglected tropical disease control 
under the umbrella of the HIV/AIDS, tuberculosis, and 
malaria global partnerships are potentially huge. 
 As noted above, integrated control of the neglected 
tropical diseases relies on the appropriate use of three 
anthelmintics—albendazole, ivermectin, and praziquantel—
and the antibacterial agent azithromycin. In addition to 
affecting STH and schistosome deworming, ectoparasite 
control, and control or elimination of LF and onchocerciasis, 
the three anthelmintics would help to reduce anemia as 
well as the progression of disease resulting from HIV/AIDS, 
tuberculosis, and malaria [62,65]. In Senegal, deworming for 
STH infections was shown to be equivalent to the protection 
from malaria conferred by the sickle cell trait [62,64], and has 
the added effect of restoring T cell responses to mycobacterial 
antigens in helminth-exposed individuals before and after 
BCG vaccination [107,108]. In Zimbabwe, treatment for 
schistosomiasis reduced the rate of HIV-1 viral replication 
and increased CD4 cell counts among individuals who were 
coinfected [99], although this phenomenon was not observed 
in Ugandans who were coinfected [109]. Therefore, it may 
be important to consider local and geographical differences 
when evaluating the impact of deworming on coinfections.
 In addition to the beneﬁ cial effects of deworming 
on children already mentioned, antenatal anthelmintic 
treatment was shown recently to reduce maternal morbidity 
and mortality, and improve birth weight and infant survival 
[110]. The community-based health-care systems set up to 
deliver neglected tropical disease drugs could be well suited 
to administer antiretrovirals, directly observed tuberculosis 
therapy, and antimalarials and bed nets. Simultaneously, 
neglected disease control would beneﬁ t from big three 
control efforts. For example, insecticide-treated bed nets used 
in malaria control are highly effective at interrupting the 
transmission of LF [70], and many antiretrovirals would be 
expected to reduce the impact of opportunistic leishmaniasis. 
 New vaccines under development for HIV/AIDS, 
tuberculosis, and malaria also need to account for the 
inﬂ uence of polyparasitism on vaccine immunogenicity [111]. 
In laboratory animals, the presence of adult hookworms 
in the intestine reduces vaccine-speciﬁ c antibody titer and 
lymphoproliferation, with restoration occurring following 
deworming [112], and  S. mansoni infection reduces the 
protective efﬁ cacy of BCG vaccination [113]. Studies in 
humans also show similar effects of concurrent helminth 
infections on immune responses to tetanus and cholera 
vaccines [114,115]. However, a recently published study 
found that although maternal hookworm infection was 
associated with reduced maternal immune response to 
mycobacterial antigen, such maternal infection was also 
associated with an unexpected increase in their infants’ 
response to BCG [116].  
 Since any vaccine trial that does not control for worm 
infections could be ﬂ awed, neglected tropical disease 
control should be linked with big three vaccine development 
efforts, such as those sponsored by the International AIDS 
Vaccine Initiative (http:⁄⁄www.iavi.org), the Malaria Vaccine 
Initiative (http:⁄⁄www.malariavaccine.org), and the Aeras 
Global Tuberculosis Vaccine Foundation (http:⁄⁄www.aeras.
org). Deworming prior to vaccination may also become a 
key component in the testing process of any new generation 
vaccine against the big three. Moreover, development of 
vaccines against the neglected tropical diseases themselves, 
including vaccines for hookworm [117], schistosomiasis 
[118], and leishmaniasis [119] is also underway. In the 
future, the neglected tropical disease vaccines are expected 
to become important control tools; in the case of hookworm 
and schistosomiasis vaccines, their deployment would reduce 
the frequency of chemotherapy and, therefore, possibly 
reduce the likelihood of emerging anthelmintic drug 
resistance [120].
 Given the compelling logic and the very modest costs 
of embracing neglected tropical disease control efforts, 
it is surprising that those aiming to control the big three 
have largely ignored these opportunities and the collateral 
beneﬁ ts from reductions in anemia, worm burdens, and 
susceptibility to HIV/AIDS, tuberculosis, and malaria 
morbidity. Bilateral donors and the major big three 
partnerships should expand their portfolios to incorporate 
deworming, LF, and onchocerciasis elimination efforts, and 
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other neglected tropical disease control initiatives as a cost-
effective means to reduce the morbidity and mortality of 
HIV/AIDS, tuberculosis, and malaria. Such interventions 
are inexpensive, effective, and fully compatible with the 
MDGs, the recommendations of the UN Millennium Project 
(http:⁄⁄www.unmillenniumproject.org), the Commission 
for Africa report [48], and a Resolution of the Third Global 
Meeting of the World Health Organization Partners for 
Parasite Control [44]. While the recent report on health from 
the New Partnership for Africa’s Development (http:⁄⁄www.
nepad.org), an initiative to develop an integrated 
socioeconomic development framework for Africa with a 
mandate from the Organisation of African Unity [121], and 
the policy statement on health from the European Parliament 
[122] refer to parasitic diseases, they do not emphasize the 
interrelationships between parasitic infections and HIV/
AIDS, tuberculosis, and malaria, or the potential beneﬁ ts of 
a more holistic approach to disease control. The excellent 
safety proﬁ le of the anthelmintics and azithromycin, and the 
fact that three of the four drugs are donated free of charge 
to those who need them, would almost certainly ensure that 
neglected tropical disease control could be incorporated 
without added risk and with minimal costs. 
 Scaling Up Disease Control
 The international community has started to address issues 
of scaling up disease control in the developing world. HIV/
AIDS, tuberculosis, and malaria have been given a ﬁ nancing 
mechanism for scale up through the establishment of the 
Global Fund to Fight AIDS, Tuberculosis, and Malaria. The 
scaling up of malaria control was explicitly featured in the ﬁ nal 
outcome document of the September 2005 UN World Summit 
(http:⁄⁄www.un.org/ga/59/hlpm_rev.2.pdf). The World Bank 
and other donors are similarly identifying new channels and 
ﬁ nancing strategies for infectious disease control [123]. 
 The scale up of control measures vis-à-vis the neglected 
tropical diseases can be readily added to these ongoing 
initiatives, possibly by ﬁ rst incorporating neglected tropical 
disease control into model health systems. Two great 
examples are the Tanzania Essential Health Interventions 
Project—a research and development partnership between 
Tanzania’s Ministry of Health and Canada’s International 
Development Research Centre (http:⁄⁄www.idrc.ca)—and 
the Millennium Village Project, a new development project 
guided by a scientiﬁ c council at the Earth Institute at 
Columbia University (http:⁄⁄www.earth.columbia.edu/mvp) 
and based on the recommendations of the UN Millennium 
Project. The Millennium Village Project will provide a 
framework for scaling up control of the neglected tropical 
diseases alongside other health interventions in project 
sites in ten African countries, with rigorous surveying and 
monitoring of the MDG-based indicators. These issues will be 
subjects of important discussions at a January 2006 summit 
in Stockholm, Sweden, as both programs recognize that 
it is the countries themselves who must eventually deﬁ ne 
appropriate policy and priority, often through a decentralized 
system of district-level teams. Attending to the neglected 
tropical diseases will require committed support for baseline 
mapping of the prevalence of the individual neglected 
tropical diseases, scientiﬁ cally vetted treatment protocols, 
and appropriate alignment of these efforts with regional and 
national health policies. 
 Conclusion
 The neglected tropical diseases have joined the ranks of the 
big three to create a 21st century “gang of four.” For too 
long the big three partnerships have worked in isolation, as 
have the vertical programs against the individual neglected 
tropical diseases. The recent Paris Declaration emanating 
from the High-Level Forum on the Health MDGs calls for 
greater harmonization and collaboration across the major 
global health partnerships and the commended efforts by 
the smaller neglected tropical disease partnerships (the 
minor global health partnerships) to integrate these activities 
[124]. In the future, policy must be driven by the reality of 
the biological and epidemiological interactions between the 
big three and the neglected tropical diseases. Coordination 
of the major and minor global health partnerships and their 
associated research communities would give a signiﬁ cant 
thrust to the efforts now underway to reduce disease and 
poverty worldwide.  
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